1. bookVolumen 71 (2021): Edición 1 (March 2021)
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

An analytical “quality by design” approach in RP-HPLC method development and validation for reliable and rapid estimation of irinotecan in an injectable formulation

Publicado en línea: 20 Jul 2020
Volumen & Edición: Volumen 71 (2021) - Edición 1 (March 2021)
Páginas: 57 - 79
Aceptado: 02 Apr 2020
Detalles de la revista
License
Formato
Revista
eISSN
1846-9558
Primera edición
28 Feb 2007
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. S. Negoro, N. Masuda, Y. Takada, T. Sugiura, S. Kudoh, N. Katakami, Y. Ariyoshi, Y. Ohashi, H. Nittani and M. Fukuoka, Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer, Br. J. Cancer.88 (2003) 335–341; https://doi.org/10.1038/sj.bjc.660072510.1038/sj.bjc.6600725Search in Google Scholar

2. Y. Takahashi, H. Kitakata, K. Yamashita, K. Yasumoto, K. Omote, T. Minamoto and M. Mai, Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer, Surg. Today34 (2004) 246–250; https://doi.org/10.1007/s00595-003-2688-y10.1007/s00595-003-2688-ySearch in Google Scholar

3. M. J. Hageman and W. Morozowich, Case Study: Irinotecan (CPT-11), a Water-Soluble Prodrug of SN-38, in Prodrugs: Challenges and Rewards – Part 1 (Eds. V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag and J. W. Tilley), Berlin 2007, pp. 1269–1279 (Book Series: Biotechnology: Pharmaceutical Aspects)10.1007/978-0-387-49785-3_44Search in Google Scholar

4. L. P. Rivory, Irinotecan (CPT-11): A brief overview, Clin. Exp. Pharmacol. Physiol.23 (1996) 1000–1004.10.1111/j.1440-1681.1996.tb01158.xSearch in Google Scholar

5. H. Wei, J. Song, H. Li, Y. Li, S. Zhu, X. Zhou, X. Zhang and L. Yang, Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation, Asian J. Pharm. Sci.8 (2013) 303–311; https://doi.org/10.1016/j.ajps.2013.10.00610.1016/j.ajps.2013.10.006Search in Google Scholar

6. N. Taneja, V. Gota, M. Gurjar and K. K. Singh, Development and validation of high-performance liquid chromatographic method for quantification of irinotecan and its active metabolite SN-38 in colon tumor bearing NOD/SCID mice plasma samples: Application to pharmacokinetic study, Acta Chromatogr.31 (2019) 166–172; https://doi.org/10.1556/1326.2018.0037010.1556/1326.2018.00370Search in Google Scholar

7. E. Gravel, P. Bourget, L. Mercier and A. Paci, Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: Application to camptothecin derivatives, J. Pharm. Biomed. Anal.39 (2005) 581–586; https://doi.org/10.1016/j.jpba.2005.05.01010.1016/j.jpba.2005.05.010Search in Google Scholar

8. S. Poujol, F. Pinguet, F. Malosse, C. Astre, M. Ychou, S. Culine and F. Bressolle, Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies, Clin. Chem.49 (2003) 1900–1908; https://doi.org/10.1373/clinchem.2003.02348110.1373/clinchem.2003.023481Search in Google Scholar

9. T. S. Owens, H. Dodds, K. Fricke, S. K. Hanna and K. R. Crews, High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma, J. Chromatogr. B788 (2003) 65–74; https://doi.org/10.1016/S1570-0232(02)01016-410.1016/S1570-0232(02)01016-4Search in Google Scholar

10. S. Bardin, W. Guo, J. L. Johnson, S. Khan, A. Ahmad, J. X. Duggan, J. Ayoub and I. Ahmad, Liquid chromatographic–tandem mass spectrometric assay for the simultaneous quantification of Camptosar® and its metabolite SN-38 in mouse plasma and tissues, J. Chromatogr. A1073 (2005) 249–255; https://doi.org/10.1016/j.chroma.2004.08.06010.1016/j.chroma.2004.08.06015909526Search in Google Scholar

11. M. I. Rodríguez Cáceres, I. Durán-Merás, N. E. O. Soto, P. L. L. de Alba and L. L. Martínez, Spec-trofluorimetric determination of irinotecan in the presence of oxidant agents and metal ions, Talanta74 (2008) 1484–1491; https://doi.org/10.1016/j.talanta.2007.09.02510.1016/j.talanta.2007.09.025Search in Google Scholar

12. M. Tariq, L. M. Negi, S. Talegaonkar, F. J. Ahmad, Z. Iqbal and A. M. Khan, Liquid chromatographic method for irinotecan estimation: Screening of P-gp modulators, Indian J. Pharm. Sci.77 (2015) 14–23; https://doi.org/10.4103/0250-474X.15157710.4103/0250-474X.151577Search in Google Scholar

13. P. Shende and R. Gaud, Validated RP-HPLC analysis of irinotecan HCl in the bulk material and in pharmaceutical formulations, Acta Chromatogr.21 (2009) 71–82; https://doi.org/10.1556/AChrom.21.2009.1.610.1556/AChrom.21.2009.1.6Search in Google Scholar

14. T. Xuan, J. A. Zhang and I. Ahmad, HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38, J. Pharm. Biomed. Anal.41 (2006) 582–588; https://doi.org/10.1016/j.jpba.2005.10.05110.1016/j.jpba.2005.10.051Search in Google Scholar

15. L. Kumar, M. S. Reddy, R. S. Managuli and K. G. Pai, Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles, Saudi Pharm. J.23 (2015) 549–555; https://doi.org/10.1016/j.jsps.2015.02.00110.1016/j.jsps.2015.02.001Search in Google Scholar

16. R. S. Managuli, L. Kumar, A. D. Chonkar, R. K. Shirodkar, S. Lewis, K. B. Koteshwara, M. S. Reddy and S. Mutalik, Development and validation of a stability-indicating RP-HPLC method by a statistical optimization process for the quantification of asenapine maleate in lipidic nanoformulations, J. Chromatogr. Sci.54 (2016) 1290–1300; https://doi.org/10.1093/chromsci/bmw06210.1093/chromsci/bmw062Search in Google Scholar

17. M. S. Reddy, L. Kumar, Z. Attari and R. Verma, Statistical optimization of extraction process for the quantification of valsartan in rabbit plasma by a HPLC method, Indian J. Pharm. Sci.79 (2017) 16–28; https://doi.org/10.4172/pharmaceutical-sciences.100019610.4172/pharmaceutical-sciences.1000196Search in Google Scholar

18. J. Shao, W. Cao, H. Qu, J. Pan and X. Gong, A novel quality by design approach for developing an HPLC method to analyze herbal extracts: A case study of sugar content analysis, PLoS One13 (2018) e0198515 (15 pages); https://doi.org/10.1371/journal.pone.019851510.1371/journal.pone.0198515Search in Google Scholar

19. A. H. Schmidt and I. Molnár, Using an innovative quality-by-design approach for development of a stability indicating UHPLC method for ebastine in the API and pharmaceutical formulations, J. Pharm. Biomed. Anal.78–79 (2013) 65–74; https://doi.org/10.1016/j.jpba.2013.01.03210.1016/j.jpba.2013.01.032Search in Google Scholar

20. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva, November 2005; https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access March 20, 2019Search in Google Scholar

21. J. J. Kirkland, M. A. van Straten and H. A. Claessens, High pH mobile phase effects on silica-based reversed-phase high-performance liquid chromatographic columns, J. Chromatogr. A.691 (1995) 3–19; https://doi.org/10.1016/0021-9673(94)00631-I10.1016/0021-9673(94)00631-ISearch in Google Scholar

22. R. Khurana, S. Beg, D. Lal, O. P. Katare and B. Singh, Analytical quality by design approach for development of a validated bioanalytical UPLC method of docetaxel trihydrate, Curr. Pharm. Anal.11 (2015) 180–192; https://doi.org/10.2174/157341291166615012123415010.2174/1573412911666150121234150Search in Google Scholar

23. M. Herneisey, L. Liu, E. Lambert, N. Schmitz, S. Loftus and J. M. Janjic, Development of theranostic perfluorocarbon nanoemulsions as a model non-opioid pain nanomedicine using a Quality by Design (QbD) approach, AAPS PharmSciTech20 (2019) Article ID 65; https://doi.org/10.1208/s12249-018-1287-610.1208/s12249-018-1287-630627887Search in Google Scholar

24. J. Dolan, A Guide to HPLC and LC-MS Buffer Selection. ACE HPLC Columns – Ultra Inert Base-Deactivated HPLC Columns, Advanced Chromatogrpahy Technologies, Aberdeen; https://www.hplc.eu/Downloads/ACE_Guide_BufferSelection.pdf; last access April 5, 2019.Search in Google Scholar

25. A. Bozkir and O. M. Saka, Formulation and investigation of 5-FU nanoparticles with factorial design-based studies, Farmaco60 (2005) 840–846; https://doi.org/10.1016/j.farmac.2005.06.01610.1016/j.farmac.2005.06.01616087183Search in Google Scholar

26. Indian Pharmacopoeia 2007, Government of Indian, Ministry of Health & Family Welfare, The Indian Pharmacopoeia Commission, Ghaziabad 2007.Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo